Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Clinical trial NCT07179783 · RECRUITING

Trial details

NCT number: NCT07179783
Sponsor: Tianjin Medical University Second Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-Resistant Prostate Adenocarcinoma With Neuroendocrine Differentiation

Start date: 2025-09-22
Primary completion: 2027-06-30
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.